title: The effect of Prometheus device on laboratory markers of inflammation and tissue regeneration in acute liver failure management.
abstract: Prometheus, based on modified fractionated plasma separation and adsorption (FPSA) method, is used in the therapy of acute liver failure as a bridge to liver transplantation. As the therapeutic effect of Prometheus is caused not only by the elimination of terminal metabolites, the aim of the study was to identify the effect of FPSA on the levels of cytokines and markers of inflammation and liver regeneration. Previous studies assessing cytokine levels involved mostly acute-on-chronic liver failure patients. Data concerning markers of inflammation and liver regeneration are not published yet. Eleven patients (three males, eight females) with acute liver failure were investigated. These patients underwent 37 therapeutic sessions on Prometheus device. Before and after each treatment, the plasma levels of selected cytokines, tumor necrosis factor alpha (TNFα), C-reactive protein (CRP), procalcitonin (PCT), hepatocyte growth factor (HGF), and α(1) fetoprotein, were measured, and the kinetics of their plasma concentrations was evaluated. Before the therapy, elevated levels of interleukin (IL)-6, IL-8, IL-10, TNFα, CRP, and PCT were detected. The level of TNFα, CRP, PCT, and α(1) fetoprotein decreased significantly during the therapy. In contrast, an increase of HGF was detected. The decline of IL-6, IL-8, and IL-10 concentrations was not significant. Our results show that Prometheus is highly effective in clearing inflammatory mediators responsible for systemic inflammatory response syndrome and affects the serum levels of inflammatory and regeneration markers important for management of acute liver failure.
authors.affiliation: Institute for Clinical and Experimental Medicine, Anesthesiology and Intensive Care Unit, Videnska 1958/9, Prague, Czech Republic. mirc@medicon.cz
authors.forename: M
authors.initials: M
authors.lastname: Rocen
authors.forename: E
authors.initials: E
authors.lastname: Kieslichova
authors.forename: D
authors.initials: D
authors.lastname: Merta
authors.forename: E
authors.initials: E
authors.lastname: Uchytilova
authors.forename: Y
authors.initials: Y
authors.lastname: Pavlova
authors.forename: J
authors.initials: J
authors.lastname: Cap
authors.forename: P
authors.initials: P
authors.lastname: Trunecka
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D002116:Calcitonin / Q000097:blood; D015740:Calcitonin Gene-Related Peptide; D018153:Czech Republic; D004797:Enzyme-Linked Immunosorbent Assay; D004867:Equipment Design; D005260:Female; D006464:Hemoperfusion / Q000295:instrumentation*; D017228:Hepatocyte Growth Factor / Q000097:blood; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007378:Interleukins / Q000097:blood; D017114:Liver Failure, Acute / Q000097:blood / Q000276:immunology / Q000628:therapy*; D008115:Liver Regeneration; D019164:Liver, Artificial; D008297:Male; D008875:Middle Aged; D011498:Protein Precursors / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: C097353:AFP protein, human; D015415:Biomarkers; C000606589:CALCA protein, human; C066855:HGF protein, human; D018836:Inflammation Mediators; D007378:Interleukins; D011498:Protein Precursors; D014409:Tumor Necrosis Factor-alpha; D000509:alpha-Fetoproteins; D017228:Hepatocyte Growth Factor; D002116:Calcitonin; D002097:C-Reactive Protein; D015740:Calcitonin Gene-Related Peptide